 Akari Therapeutics, Plc AKTX, a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement andor leukotriene systems are implicated, today announced that it has entered into definitive agreements with certain accredited investors, the majority of whom are existing investors of the Company, including Dr. Ray Prudo, Akaris Chairman, to receive gross proceeds of approximately 6 million through the private placement of its equity securities. In connection with the offering, the Company will issue unregistered American Depository Shares ADSs at a purchase price of 1.70 per ADS. The ADS and warrants described above are being offered in a private placement under Section 4a2 of the Securities Act of 1933, as amended the Act, and Regulation D promulgated thereunder and, along with the ADSs issuable upon exercise of the warrants, have not been registered under the Act, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. 